Genetic frontotemporal dementia (FTD) is a progressive and heterogeneous neurodegenerative disease most frequently caused by an autosomal dominant genetic mutation in the microtubule-associated protein tau (MAPT), progranulin (GRN), or chromosome 9 open reading frame 72 (C9orf72).1 Changes in grey and white matter regions measured by magnetic resonance imaging (MRI) have been reported many years before symptoms develop in previous studies,2-4 but the exact relationship of such brain changes to clinical progression is yet to be fully understood. The gene discussed is GRN; the disease is neurodegenerative disease.